Tetrahydroberberine combined with protopanaxadiol synergistically improves sleep in PCPA-induced insomnia in rats
The combination of tetrahydroberberine (THB) and protopanaxadiol (PPD) showed synergistic effects in rats with PCPA-induced insomnia, shortening sleep latency by 56.2% and prolonging sleep duration by 112.8% compared to the model group, outperforming either monotherapy. The treatment also restored body weight, reduced hippocampal damage, balanced neurotransmitters, and modulated the microbiota-gut-brain axis and PI3K/AKT/AGE-RAGE pathways.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Tetrahydroberberine combined with protopanaxadiol synergistically improves sleep in PCPA-induced insomnia in rats The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 26/100 (low).
The Claim
Tetrahydroberberine combined with protopanaxadiol synergistically improves sleep in PCPA-induced insomnia in rats
This conclusion is most relevant to: PCPA-induced insomnia rat model (Sprague-Dawley rats).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Synergistic Therapeutic Effects of Tetrahydroberberine Combined with Protopanaxadiol on PCPA-Induced Insomnia in Rats: Involvement of the Microbiota-Gut-Brain Axis and Regulation of PI3K/AKT/AGE-RAGE Pathways. (Pharmaceuticals (Basel, Switzerland), 2026) —
How It Works
The proposed biological pathway:
- ▸Combined THB+PPD restores gut microbial homeostasis (increases beneficial Lactobacillus)
- ▸Modulates glycine-serine-threonine metabolic pathway
- ▸Activates PI3K/AKT neurotrophic pathway (upregulates p-PI3K and p-AKT)
- ▸Inhibits AGE/RAGE pro-inflammatory axis (downregulates RAGE)
- ▸Upregulates tight junction proteins (ZO-1, Occludin) enhancing blood-brain barrier integrity
- ▸Result: Reduced HPA axis overactivation, balanced neurotransmitters, decreased inflammation, and improved sleep
Who Might Benefit
Evidence fit by population:
- ▸PCPA-induced insomnia rat model (Sprague-Dawley rats)
Recommended Dose
Not specified in abstract
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Animal model (rats) limits direct generalizability to humans
- ▸Dose and administration details not provided in abstract, preventing clinical translation
Frequently Asked Questions
What is tetrahydroberberine (THB)?▼
Tetrahydroberberine is a natural alkaloid derived from plants like Coptis chinensis, known for sedative and neuroprotective properties.
How does the THB+PPD combination compare to diazepam in this study?▼
The abstract mentions a diazepam group but does not provide direct comparative effect sizes; however, the combination showed synergistic effects superior to either THB or PPD alone.
What is the microbiota-gut-brain axis?▼
It is a bidirectional communication system between the gut microbiome and the brain, involving neural, endocrine, and immune pathways, which this study suggests is modulated by THB+PPD to improve sleep.
Could this combination be used for human insomnia?▼
This is a preclinical animal study; human trials are needed to confirm safety and efficacy before any clinical use.
References
- 1.Li M, Wang Y, Liang Z, Li H, Zhao Y, Kong L, Guo N, Dai G, Zhang G, Lu X, Yao J. “Synergistic Therapeutic Effects of Tetrahydroberberine Combined with Protopanaxadiol on PCPA-Induced Insomnia in Rats: Involvement of the Microbiota-Gut-Brain Axis and Regulation of PI3K/AKT/AGE-RAGE Pathways..” Pharmaceuticals (Basel, Switzerland), 2026. PMID: 41901236 DOI: 10.3390/ph19030390